Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a wearable device prevent dangerous blood sugar swings in hospital patients?

NCT ID NCT04230694

First seen May 01, 2026 · Last updated Jun 22, 2026 · Updated 8 times

Summary

This pilot study tested a continuous glucose monitor (CGM) in 40 hospitalized adults with type 1 or type 2 diabetes. The goal was to see if using the device could help detect and reduce episodes of low and high blood sugar. Researchers compared CGM readings to standard care to gather evidence for wider hospital use.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Baylor Scott & White Medical Center - Temple

    Temple, Texas, 76508, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Dexcom Generation 6 CGM device

What this could lead to

If successful, this could show that continuous glucose monitoring is a practical and effective way to manage blood sugar in hospitalized patients with diabetes.

What could go wrong

This is a small pilot study with only 40 participants, so results may not apply to all patients. The device may not be accurate in all hospital settings.

Conditions

The condition(s) this trial relates to.

diabetes mellitus hyperglycemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.